P

Piramal Pharma Ltd
NSE:PPLPHARMA

Watchlist Manager
Piramal Pharma Ltd
NSE:PPLPHARMA
Watchlist
Price: 180 INR 0.64% Market Closed
Market Cap: 238B INR

Piramal Pharma Ltd
Selling, General & Administrative

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Piramal Pharma Ltd
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
P
Piramal Pharma Ltd
NSE:PPLPHARMA
Selling, General & Administrative
-₹29.6B
CAGR 3-Years
-81%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Selling, General & Administrative
-₹78.8B
CAGR 3-Years
6%
CAGR 5-Years
0%
CAGR 10-Years
-14%
Cipla Ltd
NSE:CIPLA
Selling, General & Administrative
-₹50.6B
CAGR 3-Years
-11%
CAGR 5-Years
-10%
CAGR 10-Years
-9%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Selling, General & Administrative
-₹106.1B
CAGR 3-Years
-11%
CAGR 5-Years
-10%
CAGR 10-Years
-8%
Lupin Ltd
NSE:LUPIN
Selling, General & Administrative
-₹41.7B
CAGR 3-Years
-12%
CAGR 5-Years
-7%
CAGR 10-Years
-8%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Selling, General & Administrative
-₹23.4B
CAGR 3-Years
-14%
CAGR 5-Years
-10%
CAGR 10-Years
-11%
No Stocks Found

Piramal Pharma Ltd
Glance View

Market Cap
238B INR
Industry
Pharmaceuticals

Piramal Pharma Ltd. has embarked on a remarkable journey that reflects the dynamic world of pharmaceuticals and healthcare. Emerging from the rich tapestry of the Piramal Group's diverse business ventures, it has carved out a distinctive place for itself in the global pharmaceutical landscape. The company primarily navigates through three major streams: Contract Development and Manufacturing Organization (CDMO), Critical Care, and Consumer Products. Its CDMO division is the backbone, providing end-to-end solutions spanning the entire drug lifecycle, from development through to commercial manufacturing. By offering tailored solutions to pharmaceutical companies globally, Piramal Pharma not only strengthens its revenue streams but also builds lasting partnerships with some of the world’s leading pharmaceutical innovators. Beyond the realm of CDMO, Piramal Pharma's Critical Care segment specializes in catering to the acute care sector, dealing especially with inhalation anesthesia and pain management solutions. This division operates globally, emphasizing a diligent supply chain that ensures these life-sustaining products reach hospitals and clinics around the world. Meanwhile, its Consumer Products business makes a concerted effort to touch lives in a different manner—through over-the-counter health solutions that meet everyday health concerns of countless individuals. Operating at this unique intersection where science meets humanity, Piramal Pharma not only thrives through product sales but also invests heavily in R&D, seeking out innovative ways to address evolving market needs and inch its way forward in the competitive pharmaceutical arena.

PPLPHARMA Intrinsic Value
150.62 INR
Overvaluation 16%
Intrinsic Value
Price
P

See Also

What is Piramal Pharma Ltd's Selling, General & Administrative?
Selling, General & Administrative
-29.6B INR

Based on the financial report for Mar 31, 2025, Piramal Pharma Ltd's Selling, General & Administrative amounts to -29.6B INR.

What is Piramal Pharma Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 3Y
-81%

Over the last year, the Selling, General & Administrative growth was -13%. The average annual Selling, General & Administrative growth rates for Piramal Pharma Ltd have been -81% over the past three years .

Back to Top